- Acquired by Advaxis, Jan 2023
- Raised $30M funding round led by Novartis, May 2019
- Raised $17M funding round, Apr 2018
About
Ayala Pharmaceuticals is a clinical-stage precision oncology company dedicated to developing and commercializing potential small molecule therapeutics for patients suffering from rare and aggressive cancers, especially in genetically defined patient populations. Ayalas product candidates, AL101 and AL102, are designed to target cancer by addressing the underlying key drivers of tumor growth. Both product candidates target the aberrant activation of the Notch pathway with gamma-secretase inhibitors (GSIs). By developing drugs designed to inhibit Notch pathway activation, Ayala is enabling personalized therapy for cancer patients. In 2017, the company entered into an exclusive worldwide license agreement with Bristol-Myers Squibb for its gamma-secretase inhibitors. Ayalas lead product, AL101, granted orphan drug designation by the FDA in 2019, has completed preclinical and phase 1 studies. A phase 2 study (ACCURACY) for AL101 in patients with adenoid cystic carcinoma bearing activated Notch mutations has been initiated. In 2018, Ayala entered into a deal with Novartis to develop and commercialize AL102 in combination with BCMA-targeting agents in multiple myeloma. In addition, Ayala is evaluating AL102 as an inhibitor of the Notch pathway in hematologic cancers.
Funding history · 4 rounds · $102.0M total
Q&A
- What is Ayala Pharmaceuticals' current status?
- Ayala Pharmaceuticals was acquired by Advaxis in January 2023.
- What is Ayala Pharmaceuticals' primary focus?
- Ayala Pharmaceuticals is a clinical-stage precision oncology company focused on developing and commercializing small molecule therapeutics for patients with rare and aggressive cancers, particularly in genetically defined populations.
- Which product candidates are being developed by Ayala Pharmaceuticals?
- Ayala Pharmaceuticals is developing AL101 and AL102, both designed to target cancer by addressing the aberrant activation of the Notch pathway with gamma-secretase inhibitors (GSIs).
- When was Ayala Pharmaceuticals founded?
- Ayala Pharmaceuticals was founded in January 2017.
- What was the total amount of funding raised by Ayala Pharmaceuticals?
- Ayala Pharmaceuticals raised a total of $102,000,000 in funding.
- Which companies invested in Ayala Pharmaceuticals' May 2019 funding round?
- In May 2019, Novartis and Shavit Capital Fund were among the investors in.
- What was a key licensing agreement for Ayala Pharmaceuticals in 2017?
- In 2017, Ayala Pharmaceuticals entered into an exclusive worldwide license agreement with Bristol-Myers Squibb for its gamma-secretase inhibitors.
- What is the employee count for Ayala Pharmaceuticals?
- Ayala Pharmaceuticals has an employee count in the 11-50 range.
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | ayalapharma.com |
|---|---|
| linkedin.com/company/18445059 |
Identifiers & details
| Founded | 2017-1 |
|---|---|
| Employees (exact) | 30 |
| Offices | Wilmington |
| Status reason | Acquired by Advaxis on Jan, 2023 |
Acquisitions & public offerings
Acquired by Advaxis 2023-01
Radar intelligence
Patents
| EPO | 16 |
|---|
Web history (Wayback)
| Domain | ayalapharma.com |
|---|
Certificate / subdomain footprint
| Subdomains | 24 |
|---|